Impact Factor 3.582

The world's most-cited Neurosciences journals

Original Research ARTICLE Provisionally accepted The full-text will be published soon. Notify me

Front. Aging Neurosci. | doi: 10.3389/fnagi.2018.00424

Metabolite Profile of Alzheimers Disease in the Frontal Cortex as Analyzed by HRMAS 1H NMR

  • 1Department of Radiology, People's Hospital of Longhua, Shenzhen, China
  • 2Graduate School of Jiangxi Medical College, Nanchang University, China
  • 3Department of Radiology, Emory University School of Medicine, United States
  • 4Yiwei Medical Technology, Inc., Spratly Islands

Background: Investigation on neurochemical changes in the frontal cortex in individuals with Alzheimer’s disease (AD) and different Apolipoprotein E (APOE) genotypes using ex vivo solid-state high-resolution NMR analysis may lead to better understanding on neurochemistry associated to AD and new AD-specific metabolite biomarkers that might potentially improve the clinical diagnosis of AD.
Methods: Intact tissue samples of the frontal cortex were obtained from 11 patients and 11 age-matched non-demented controls. Metabolite profiles in all samples were analyzed ex vivo using solid-state high-resolution magic angle spinning (HRMAS) 600 MHz 1H nuclear magnetic resonance (NMR). Logistic regression analysis was used to rank metabolites based on their level of contribution in differentiating AD patients and controls, and different AD-associated APOE genotypes (APOE 4 vs. APOE 3).
Results: Tissue samples from AD patients showed significantly lower NAA/Cr (p = 0.011), Ace/Cr (p = 0.027), GABA/Cr (p = 0.005), Asp/Cr (p < 0.0001), mI/Cr (p < 0.0001), and Tau/Cr (p = 0.021), and higher PCho/Cr (p < 0.0001), GPCho/Cr (p < 0.0001), and α&β-Glc/Cr (p < 0.0001) than did controls. Specifically, a newly observed resonance at 3.71 ppm, referred to as α&β-Glc, was observed in 90.9% of AD samples (10/11). Samples with APOE 4 also exhibited higher PCho/Cr (p = 0.0002), GPCho/Cr (p = 0.0001), α&β-Glc/Cr (p < 0.0001), and lower Asp/Cr (p = 0.004) and GABA/Cr (p = 0.04) than samples with APOE 3. In the logistic regression analysis, PCho, GPCho, ASP, and α&β-Glc were found to be the most relevant metabolites for differentiating AD patients and controls, and different APOE genotypes.
Conclusions: HRMAS 1H NMR with high spectral resolution and sensitivity offers a powerful tool for gaining quantitative information on AD associated neurochemical changes. There are important neurochemical differences in the frontal cortex between AD patients and controls, and between those with different APOE genotypes. The resonance (α&β-Glc) found at 3.71 ppm in AD patients may be further investigated for its potential in diagnosis and monitoring of AD.

Keywords: Nuclear magnetic resonance spectroscopy (NMR), Alzheimer’s disease (AD), Metabolic change, Neurochemistry, Brain

Received: 12 Sep 2018; Accepted: 06 Dec 2018.

Edited by:

Changiz Geula, Northwestern University, United States

Reviewed by:

Ramesh Kandimalla, Texas Tech University Health Sciences Center, United States
Yu Zhang, VA Palo Alto Health Care System, United States
Ying Han, Xuanwu Hospital, Capital Medical University, China  

Copyright: © 2018 Zhang, Liu, Ji, Liu, Liu, Wang and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Prof. Liya Wang, Nanchang University, Graduate School of Jiangxi Medical College, Nanchang, 330031, Jiangxi Province, China, lwang30@emory.edu